Metraipolis › archive › dc_e4b392018032

Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning… — Europe PMC PMID:42303794

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42303794
DOI
10.1038/s43856-[numero omesso]-3
License (as archived)
solo-consultazione
Archived
2026-10-19T09:21:40.473Z
SHA-256 of the archived text
12c9f400bb6a93ffcb2c5c91a9163c56aab5dc7dbec35e5f620d8cda4063602a
Stable URL of this page
https://metraipolis.com/documento/dc_e4b392018032

How to cite

Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning… — Europe PMC PMID:42303794 — Europe PMC (en), https://europepmc.org/article/MED/42303794 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e4b392018032 (Metraipolis archive dc_e4b392018032, sha256 12c9f400bb6a93ffcb2c5c91a9163c56aab5dc7dbec35e5f620d8cda4063602a)
BibTeX
@misc{dce4b392018032,
  title = {Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning… — Europe PMC PMID:42303794},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42303794},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e4b392018032; sha256 12c9f400bb6a93ffcb2c5c91a9163c56aab5dc7dbec35e5f620d8cda4063602a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42303794. Agents can read the archived copy with the MCP tool read_document.